Skip to main content

Table 3 Predictors of Sustained Virologic Response in HCV treatment recipients

From: HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus

Effect

Unadjusted OR, 95% CI

Adjusted OR, 95% CI

DM diagnosis

1.09 (1.05-3.47)

1.37 (0.54-3.46)

Age at first assessment

1.03 (1.02-1.05)

1.02 (1.01-1.05)

Male sex

0.82 (0.57-1.18)

1.54 (1.33-2.72)

Genotype

 G1

0.65 (0.32-1.35)

1.48 (0.58-3.79)

 G2

0.64 (0.25-1.66)

1.43 (0.78-2.61)

 G3

0.51 (0.24-1.12)

0.38 (0.09-1.70)

 Other

Ref.

Ref.

Cirrhosis by FibroScana

1.17 (0.79-1.72)

1.40 (0.71-2.76)

Steatosis by Fibroscanb

1.26 (0.71-2.23)

1.44 (0.74-2.80)

Race

 Caucasian

1.14 (0.78-1.67)

0.74 (0.34-1.62)

 Non-Caucasian

Ref.

Ref.

HIV co-infection

1.15 (0.48-2.88)

1.49 (0.48-4.65)

Psychiatric illness

0.95 (0.68-1.33)

0.59 (0.33-1.04)

Hepatocellular carcinoma

0.86 (0.37-2.00)

1.05 (0.13-8.74)

Currently employed

2.24 (1.32-3.81)

2.10 (1.06-4.15)

History of alcohol use

0.77 (0.54-1.11)

1.17 (0.66-2.09)

Incarceration history

0.77 (0.54-1.11)

0.56 (0.31-1.03)

IDU history

0.70 (0.48-1.03)

0.55 (0.28-1.10)

  1. Denominator represents ntotal – nmissing data
  2. aCirrhosis by transient elastography defined as >12.5 kPa
  3. bSteatosis by transient elastography defined as Controlled Attenuation Parameter score >300 dB/m